Medicon Hellas
Market Cap
€8.8m
Last Updated
2020/05/26 14:42 UTC
Data Sources
Company Financials
Executive Summary
Medicon Hellas S.A. operates in the diagnostics industry.
Rewards
PE ratio (21.8x) is below the Medical Equipment industry average (38.6x)
Risk Analysis
+ 1 more risk
Snowflake Analysis
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Medicon Hellas's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MEDIC's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.5%
MEDIC
5.8%
GR Medical Equipment
1.6%
GR Market
1 Year Return
14.3%
MEDIC
24.7%
GR Medical Equipment
-15.7%
GR Market
Return vs Industry: MEDIC underperformed the Greek Medical Equipment industry which returned 21.8% over the past year.
Return vs Market: MEDIC exceeded the Greek Market which returned -13.2% over the past year.
Shareholder returns
| MEDIC | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 5.8% | 1.6% |
| 30 Day | -1.0% | 11.0% | 2.5% |
| 90 Day | -18.0% | 9.2% | -22.4% |
| 1 Year | 14.3%14.3% | 25.8%24.7% | -12.1%-15.7% |
| 3 Year | 150.0%150.0% | 60.2%53.1% | -10.1%-18.7% |
| 5 Year | 589.7%589.7% | 129.5%110.1% | -70.5%-71.7% |
Price Volatility Vs. Market
How volatile is Medicon Hellas's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Do Medicon Hellas S.A.’s (ATH:MEDIC) Returns On Capital Compare To Peers?1 month ago | Simply Wall St
A Look At The Fair Value Of Medicon Hellas S.A. (ATH:MEDIC)2 months ago | Simply Wall St
Should We Be Cautious About Medicon Hellas S.A.'s (ATH:MEDIC) ROE Of 4.1%?Valuation
Is Medicon Hellas undervalued compared to its fair value and its price relative to the market?
21.84x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MEDIC (€2) is trading above our estimate of fair value (€1.85)
Significantly Below Fair Value: MEDIC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MEDIC is good value based on its PE Ratio (21.8x) compared to the Medical Equipment industry average (38.6x).
PE vs Market: MEDIC is poor value based on its PE Ratio (21.8x) compared to the Greek market (13x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MEDIC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MEDIC is good value based on its PB Ratio (0.9x) compared to the XE Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is Medicon Hellas forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
22.8%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicon Hellas has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Medicon Hellas's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Medicon Hellas competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Medicon Hellas performed over the past 5 years?
15.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEDIC has high quality earnings.
Growing Profit Margin: MEDIC's current net profit margins (3%) are lower than last year (24.7%).
Past Earnings Growth Analysis
Earnings Trend: MEDIC's earnings have grown by 15.7% per year over the past 5 years.
Accelerating Growth: MEDIC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MEDIC had negative earnings growth (-87.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (-1.7%).
Return on Equity
High ROE: MEDIC's Return on Equity (4.1%) is considered low.
Next Steps
Financial Health
How is Medicon Hellas's financial position?
Financial Position Analysis
Short Term Liabilities: MEDIC's short term assets (€17.9M) exceed its short term liabilities (€3.1M).
Long Term Liabilities: MEDIC's short term assets (€17.9M) exceed its long term liabilities (€15.2M).
Debt to Equity History and Analysis
Debt Level: MEDIC's debt to equity ratio (127.2%) is considered high.
Reducing Debt: MEDIC's debt to equity ratio has reduced from 794.5% to 127.2% over the past 5 years.
Debt Coverage: MEDIC's debt is not well covered by operating cash flow (19.4%).
Interest Coverage: MEDIC earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Medicon Hellas's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEDIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEDIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEDIC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEDIC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MEDIC is not paying a notable dividend for the Greek market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEDIC's dividend in 3 years as they are not forecast to pay a notable one for the Greek market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Maria Dimotsantou Sotiriou (66yo)
no data
Tenure
Ms. Maria Dimotsantou Sotiriou has been the Chairman of the Board and Chief Executive Officer of Medicon Hellas S.A. since October 31, 2014. Ms. Dimotsantou Sotiriou speaks English.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Medicon Hellas S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medicon Hellas S.A.
- Ticker: MEDIC
- Exchange: ATSE
- Founded: 1978
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €8.839m
- Shares outstanding: 4.42m
- Website: https://www.mediconsa.com
Location
- Medicon Hellas S.A.
- Melitona 5-7
- Gerakas
- 153 44
- Greece
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MEDIC | ATSE (The Athens Stock Exchange) | Yes | Ordinary Shares | GR | EUR | Jul 2001 |
| 0OKE | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jul 2001 |
Biography
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company imports and distributes analytical workstations for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems under the MLR name. It also produces instrument-specific and barcoded vial reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry comprising control and calibration, and test. In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications; supplies IT systems to healthcare providers; and produces monoclonal and polyclonal antibodies as raw materials. Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and diagnostics laboratory services. It sells its products through supermarket chains and sales outlets. Medicon Hellas S.A. was founded in 1978 and is headquartered in Gerakas, Greece.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/26 14:42 |
| End of Day Share Price | 2020/05/25 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.